1997Medical Update for PsychiatristsOpen access

Rational pharmacotherapy for Alzheimer's disease

Martin H. Steinberg, Constantine G. Lyketsos

Open full text 2 citations

Abstract

Alzheimer's disease is commonly encountered by physicians in all specialties. The anticholinesterase inhibitors tacrine and donepezil are FDA-approved to treat the disease, and many more agents are being studied. Such agents may reverse the underlying disease process, salvage injured neurons, prevent amplification of neuronal death, or replace neurotransmitter loss after cell death occurs. This article presents a rational framework for understanding at which step in the neurodegenerative sequence various agents act. A discussion of the noncognitive symptoms of Alzheimer's disease and available treatment options for these ensues, followed by the presentation of a framework for providing comprehensive care consisting of treatment of the disease and its symptoms, as well support for the patient and family/caregiver.

Open-access reader

About this research paper

What this paper is about

Alzheimer's disease is commonly encountered by physicians in all specialties. The anticholinesterase inhibitors tacrine and donepezil are FDA-approved to treat the disease, and many more agents are being studied. Such agents may reverse the underlying disease process, salvage injured neurons, prevent amplification of neuronal death, or replace neurotransmitter loss after cell death occurs. This article presents a rational framework for understanding at which step in the neurodegenerative sequence various agents act. A discussion of the noncognitive symptoms of Alzheimer's disease and available treatment options for these ensues, followed by the presentation of a framework for providing comprehensive care consisting of treatment of the disease and its symptoms, as well support for the patient and family/caregiver.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Alzheimer's disease is commonly encountered by physicians in all specialties. The anticholinesterase inhibitors tacrine and donepezil are FDA-approved to treat the disease, and many more agents are being studied. Such agents may reverse the underlying disease process, salvage injured neurons, prevent amplification of neuronal death, or replace neurotransmitter loss after cell death occurs. This article presents a rational framework for understanding at which step in the neurodegenerative sequence various agents act. A discussion of the noncognitive symptoms of Alzheimer's disease and available treatment options for these ensues, followed by the presentation of a framework for providing comprehensive care consisting of treatment of the disease and its symptoms, as well support for the patient and family/caregiver.

Key concepts: Donepezil, Tacrine, Disease, Medicine, Alzheimer's disease, Dementia, Intensive care medicine, Acetylcholinesterase

Related papers

Back to paper searchBrowse research topicsOriginal source
Rational pharmacotherapy for Alzheimer's disease — Research Paper | ScholarLens